Clinical Trial 21135

Randomized, Placebo-Controlled, Phase II Trial Examining Ustekinumab for Prevention of Graft vs. Host Disease after Allogeneic Hematopoietic Cell Transplantation

Disease Site: Unknown Sites

PI: Pidala, Joseph

Clinical Trial 21757

Phase II Study of Genomically Guided Radiation Dose Personalization in the Management of Triple Negative Breast Cancer

Disease Site: Breast

PI: Ahmed, Kamran

Clinical Trial 21790

Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC #783608) in Patients with Advanced or Metastatic Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas (NEC)

Disease Site: Other Endocrine System

PI: Haider, Mintallah

Clinical Trial 20413

Phase III Study Of Daratumumab/Rhuph20 (Nsc- 810307) + Lenalidomide Or Lenalidomide As Post-Autologous Stem Cell Transplant Maintenance Therapy In Patients With Multiple Myeloma (MM) Using Minimal Residual Disease To Direct Therapy Duration (DRAMMATIC STUDY)

Disease Site: Multiple Myeloma

PI: Nishihori, Taiga

Clinical Trial 21636

A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors

Disease Site: Breast, Colon, Prostate, Urinary Bladder

PI: Chahoud, Jad

Clinical Trial 21239

Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Disease Site: Melanoma, skin

PI: Tarhini, Ahmad

Clinical Trial 21657

Randomized Phase II/III Trial of Radiation with High-Dose Cisplatin (100 mg/m2) Every Three Weeks Versus Radiation with Low-Dose Weekly Cisplatin (40 mg/m2) for Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Disease Site: Larynx, Lip, Oral Cavity and Pharynx

PI: Chung, Christine

Clinical Trial 20026

A Phase I Study of NBTXR3 Activated by Radiotherapy for Patients with Advanced Cancers Treated with an Anti-PD1 Therapy

Disease Site: Lung

PI: Yang, George

Clinical Trial 21747

A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1)

Disease Site: Breast

PI: Han, Heather

Clinical Trial 22685

Phase 1/1B, Multicenter, Open-Label, Study of RMC-9805 in Participants with Advanced KRASG12D-Mutant Solid Tumors

Disease Site: Any Site, Esophagus, Liver, Lung, Other Digestive Organ, Pancreas, Small Intestine, Stomach

PI: Kim, Dae Won

Clinical Trial 23069

Phase 1/1b, First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF6215 in Patients with Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors

Disease Site: Any Site, Kidney, Lung, Melanoma, skin

PI: Tarhini, Ahmad

Clinical Trial 23142

Precision DC: Personalized Neoantigen Dendritic Cell Vaccine Pilot Trial for High Risk Triple Negative Breast Cancer after Neoadjuvant Therapy

Disease Site: Breast

PI: Han, Heather